Loss of negative regulators amplifies RAS signaling.
A new study identifies SPRY4 as a tumor suppressor in acute myeloid leukemia and shows that loss of SPRY4 acts as an alternative mechanism to drive RAS signaling. In addition, a paradigm of cooperativity in which combined loss of multiple negative regulators of the RAS pathway supplants the need for RAS mutations is suggested.
Genetics Division at the Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Rebecca
R
Lock
Genetics Division at the Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Karen
K
Cichowski
D000818:Animals; D063646:Carcinogenesis / Q000235:genetics*; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*; D009419:Nerve Tissue Proteins / Q000378:metabolism*; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*
D009419:Nerve Tissue Proteins; D016283:Proto-Oncogene Proteins p21(ras)